[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335860-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335860-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thymoquinone-protoflavone-hybrid-molecules-as-potential-antitumor-agents","Thymoquinone-protoflavone hybrid molecules as potential antitumor agents","","Synthesis of eight new ester-coupled thymoquinone–protoflavone hybrid compounds is developed and evaluated for cytotoxic bioactivity across multiple cancer cell lines. Compound 14 emerges as the most active hybrid, showing strong effects in all tested lines, with particularly high activity against breast cancer cells and greater selectivity toward MDA-MB-231 relative to MCF-7. Although the hybrids undergo complete hydrolysis within 24 h in cell culture conditions, compound 14 retains markedly enhanced potency against U-87 glioblastoma cells versus a 1:1 mixture of its fragments. Tumor selectivity is also highlighted by a 4.4-fold stronger effect on U-87 cells than on MRC-5 fibroblasts, with reduced selectivity when cells are co-treated using uncoupled fragments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thymoquinone-protoflavone-hybrid-molecules-as-potential-antitumor-agents/335860/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thymoquinone-protoflavone-hybrid-molecules-as-potential-antitumor-agents/335860.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was synthesized in the study?","Question",{"text":63,"@type":64},"Eight new ester-coupled hybrid compounds were synthesized from thymoquinone and protoflavone building blocks, and their bioactivity was tested against multiple cancer cell lines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which hybrid showed the best overall anticancer activity?",{"text":68,"@type":64},"Compound 14 showed promising activities across all studied cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"How did compound 14 perform in glioblastoma models and selectivity?",{"text":72,"@type":64},"Compound 14 produced about three times stronger activity against U-87 glioblastoma cells than a 1:1 mixture of its fragments, and it acted 4.4 times more strongly on U-87 cells than on MRC-5 fibroblasts.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335860,1790414735,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","PLOS ONE  \nOPEN ACCESS  \nCitation: Ahmed SHH, Tayeb BA, Gonda T, Girst G, Szőri K, Berkecz R, et al. (2024) Thymoquinoneprotoflavone hybrid molecules as potential antitumor agents. PLoS ONE 19(1): e0291567 .  \n[https://doi.org/10.1371/journal.pone.0291567](https://doi.org/10.1371/journal.pone.0291567)  \n[Editor:](Editor: Wagdy Mohamed Eldehna)[ Wagdy Mohamed Eldehna](Editor: Wagdy Mohamed Eldehna), Kafrelsheikh University Faculty of Pharmacy, EGYPT  \nReceived: August 30, 2023  \nAccepted: December 19, 2023  \nPublished: January 25, 2024  \nCopyright: © 2024 Ahmed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting Information files.  \nFunding: This work was funded by the National Research, Development and Innovation Office, Hungary (NKFIH; K134704 and TKP2021-EGA-32) by the Ministry of Innovation and Technology (A. H.) . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: The authors have declared that no competing interests exist.  \nRESEARCH ARTICLE  \nThymoquinone-protoflavone hybrid molecules as potential antitumor agents  \nSara H. H. Ahmed1, BizharA. Tayeb2, T´ımea Gonda1, G´abor Girst1, Korn´el Szőri1, R´obert Berkecz3, Istv´anZupk´o2, Ren´ata Minorics2, Attila Hunyadi1,4,5 *  \n1 Institute of Pharmacognosy, University of Szeged, Szeged, Hungary, 2 Institute of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary, 3 Institute of Pharmaceutical Analysis, University of Szeged, Szeged, Hungary, 4 HUN-REN-SZTE Biologically Active Natural Products Research Group, Szeged, Hungary, 5 Interdisciplinary Centre of Natural Products, University of Szeged, Szeged, Hungary  \n* hunyadi.[attila@szte.hu](attila@szte.hu)  \nAbstract  \nWe describe herein the synthesis of eight new ester-coupled hybrid compounds from thymoquinone and protoflavone building blocks, and their bioactivity testing against multiple cancer cell lines. Among the hybrids, compound 14 showed promising activities in all cell lines studied. The highest activities were recorded against breast cancer cell lines with higher selectivity to MDA-MB-231 as compared to MCF-7 . Even though the hybrids were found tobe completely hydrolysed in 24 h under cell culture conditions, compound 14 demonstrated a ca. three times stronger activity against U-87 glioblastoma cells than a 1:1 mixture of its fragments. Further, compound 14 showed good tumour selectivity: it acted 4.4-times stronger on U-87 cells than on MRC-5 fibroblasts. This selectivity was much lower, only ca. 1.3-times, when the cells were co-treated with a 1:1 mixture of its non-coupled fragments. Protoflavone-thymoquinone hybrids may therefore serve as potential new antitumor leads particularly against glioblastoma.  \nIntroduction  \nCancer is the second leading cause of death worldwide [ 1] . Despite the many available therapeutic options including a wide range of chemotherapeutic agents of natural origin, many limitations exist for successful treatments, e.g., severe side effects and the frequent development of resistance [2] . Because of these, there is a continuous need for effective and safe new anticancer drugs. Among different types of cancer, Glioblastoma multiforme (GBM) is a very common and particularly aggressive tumour of the brain or the spinal cord, with a very poor prognosis and limited therapeutic options [3] .  \nProtoapigenone (PA) is a fern-originated rare natural flavonoid that was found to be effective against many types of cancer in vitro and in vivo [4] . It acts as a prooxidant inducing oxidative stress and consequential DNA damage leading to apoptosis, and it was reported to influence several important antitumo","cbCaikBhIT0wgIPI","https://ap.wps.com/l/cbCaikBhIT0wgIPI","pdf",926038,13,"English","# Abstract\n# Introduction\n## Background: need for new anticancer drugs\n## Focus on glioblastoma and prognosis\n## Protoapigenone mechanisms\n## Thymoquinone mechanisms and rationale for hybridization","[{\"question\":\"What was synthesized in the study?\",\"answer\":\"Eight new ester-coupled hybrid compounds were synthesized from thymoquinone and protoflavone building blocks, and their bioactivity was tested against multiple cancer cell lines.\"},{\"question\":\"Which hybrid showed the best overall anticancer activity?\",\"answer\":\"Compound 14 showed promising activities across all studied cell lines.\"},{\"question\":\"How did compound 14 perform in glioblastoma models and selectivity?\",\"answer\":\"Compound 14 produced about three times stronger activity against U-87 glioblastoma cells than a 1:1 mixture of its fragments, and it acted 4.4 times more strongly on U-87 cells than on MRC-5 fibroblasts.\"}]","Thymoquinone-protoflavone hybrid molecules as potential antitumor agents | PDF",1790012604,33]